Lumibird SA · EURONEXT:LBIRD
Lumibird SA — H1 2022 Earnings Presentation
26 slides from Lumibird SA's earnings presentation, Sep 23, 2022
Slide 1: H1 2022 results
fa ~ a 2 ~) —l | H1 2022 results a (v4 w a < 4 Zz < x Bb w in =
Slide 2: Speakers
Speakers Marc LE FLOHIC Jean-Marc GENDRE Sai d RUTNAM President Deputy Managing Director Transforrmat GittEY CT
Slide 3: Agenda
1 Strategic direction maintained 2 H1 2022 activity: continued steady growth 3 H1 2022 results: investing in the future 4, Outlook
Slide 4: Strategic direction maintained
Zz Oo j— U Lu a AQ Y UO Lud — <— or — Y)
Slide 5: A European leader in lasers with a worldwide presence
A European leader in lasers with a worldwide presence Presence in A fast growing tech company (Revenues in M€ 126.7 g51 100.7. NOT » PEL production sites = 2016 2017 2018 2019 2020 2021 €162.5m Photonics MW Lasers and laser systems for industrial of 2021 turnover Revenues 2021 integrators, R&D centr
Slide 6: Lidar
Lidar Market trends a 8 op val ~€0.2bn al ~€0.8bn 2019 2019 Study source: Source: Laser world four com, expert interviews, desk research LUMIBIRD positioning Supplier of laser technologies to Lidar manufacturers and supplier of Lidar to Lidar integrators (from component to system) Clients / Targets
Slide 7: Defence / Space
Defence / Space Market trends Cr Study source: Strategies Unlimited LUMIBIRD positioning LUMIBIRD's offer on the 3 main laser technologies: solid state, fibre, diodes - with lasers, amplifiers and lidar systems Clients / Targets : * THALES, SAFRAN, MBDA, ARIANE, ESA, LEONARDO, US integrators Structu
Slide 8: Ophthalmology market segments
RETINA GLAUCOMA CATARACT • • 11 B$ 6.1B$ 8B$ CAGR CAGR CAGR 8.1% 3.2% 4.5% • DRY EYE • 4.9 B$ • CAGR 6.1% • 8
Slide 9: H1 2022 activity: continued steady growth
Slide 10: H1 2022 sales at €84m (+11%)
H1 2022 sales at €84m (+11%) €84.0m €75.5m Defence/Space Industrial & Scientific T +11% “7am 34.7 Photonics Lidar sensors €11.0m CES F +11% $1 2021 S51 2022 MEE Photonics MEE Medical * Growth at +11% in line with 2021 - +9% at constant scope and exchange rates * Scientific/industrial (+2%) - Medical
Slide 11: Highlights of the half-year
Highlights of the half-year " Protecting the future: Investments in H1 2022 to structure and support growth in H2 2022 and in the years to come. Continued strong demand Strong order book for H2 and 2023 Continued strategic investments Increase in stocks to serve H2 and 2023 component supply context
Slide 12: Finalization of the Saab deal
Finalization of the Saab deal Acquisition of the Saab Group's Defence Laser . . . . Renee cndenbusiness Rapid synergies and integration + 10m turnover 2021 (standalone) Integration into a new subsidiary: + 33 employees Lumibird Photonics Sweden + Designation rangefinders for air, land and sea Extens
Slide 13: H1 2022 results: investing in the future
Slide 14: Key figures June 2022
Key figures June 2022 2021-June 2022-June Change Turnover 75.4 84.0 +8.6 +11% Gross margin 47.6 52.4 +4.8 +10% %o. 63.1% 62.4% EBITDA” 14.3 11.2 G.1) 22% % 19.0% 13.3% Current operating income 8.6 3.9 (4.7) 55% %. 11.4% 4.6% _Operating income ‘Tax (1.8) (0.9) 0.9 Net income 5.1 12 (3.8) % 6.7% 1.5%
Slide 15: Evolution of the operating profit by nature
Evolution of the operating profit by nature (€m) 4,8 =2,7 8,6 ~5,2 mz 3.9 =1,0 = -0,6 Evolution exten Evolution of opens ; olution 0 iat ‘ - 2021-H1 lise expenses seroma Depreciation Capone anil Current nt costs amortization ti operating operating income income
Slide 16: Focus on the evolution of expenses
Focus on the evolution of expenses Increase in external costs: + €2.7m Travel expenses: €1.3m Resumption of post-Covid travel Return of these expenses to a lower level Finalisation of the ELLEX integration than before COVID in the 2019 Proforma '_e Marketing: + €0.7m , Resumption of post-Covid-19 tr
Slide 17: A structuring effort in the two divisions
A structuring effort in the two divisions Photonics Medical 2021-H1 2022-H1 nge (%) | 2021 -H1 2022-H2 Turnover 34.7 38.7 +11.3% 40.7 45-4 +11.5% Gross margin 23.2 24.7 +6.4% 24.4 27.7 +13.6% % 66.9% 64.0% 60.0% 61.1% EBITDA” 6.7 3.7 -43.8% 7.6 75 -2.4% % 19.2% 9.7% 18.8% 16.4% Current operating inc
Slide 18: From ROC to net income (Pdg)
From ROC to net income (Pdg) (€m) 2021-H1 2022-H1 Current operating income 8.6 3.8 Operating income 8.0 2.5 Financial result (1.1) (0.4) Taxes (1.8) (0.9) Net income 5.1 1.2 RO 2022 - impact of non-recurring items: - €1.4m Of which "Scope effect" cost: - €1.3m Financial result : Evolution of the fin
Slide 19: Balance sheet as at June 2022
Balance sheet as at 30 June 2022 ASSETS LIABILITIES (€m) 31/12/2021 30/06/2022 (€m) 31/12/2021 30/06/2022 Non-current assets 164.8 175.5 Equity 181.3 185.0 Goodwill 70.3 7d Intangibleassets 473 52.2 Non-current liabilities 108.4 105.8 Tangible assets 28.2 32.9 Non-current financial liabilities 97-9
Slide 20: Cash flow generation dedicated to securing the future
Cash flow generation dedicated to securing the future In me 2021-S1 2022-S1 Of which var. receivables/payables op 38 Of which var. stocks ~ 11.2 Cash flow (before financial expenses and taxes) 14.5 1.0 | of which orher vl 5.1 A receivables/payabies Change in WCR GD ___Gea) Taxes disbursed 1.3 (1.0)
Slide 21: A financial situation adapted to the growth strategy
A financial situation adapted to the growth strategy Evolution of the net financial debt : 49,2 | 355 20; 7,2 10,6 _0,4 L| 10,6 U 14,9 L ! othernon- 1 cash items: (entryinto the 1 scope of i consolidation / . {rental DEN 2021 Fowor ‘instil Frandelcapex Disbursement seher agreement) DFN 2022-06 ° ope
Slide 22: Outlook
Slide 23: Outlook 2022
Outlook 2022 Acceleration of growth in H2 Absorption of part of the order book Strong volume effect with accelerated growth Continued gradual price increases Production CSR
Slide 24: Confirmation of 2023 targets
Confirmation of 2023 targets Doubling of turnover €250m [—* Organic growth: 8 to 10% per year TURNOVER 2023 '—e External growth: targeted on the growth markets of Lidar, Defence and Medical Increase | Profitability _ 20 to 25% EBITDA '—e Integration, synergies, industrialisation, verticalisation Rec
Slide 25: raw
a as; c o a. raw zt
Slide 26: Distribution of capital
Distribution of capital Public Esira/Eurodyne 48,07 % 51,93 % 26